Filing Flows

Filing Flows › Companies › SkinHealth Systems › Cash flow

SkinHealth Systems cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$11.2M in Q3 2026 · $22.7M over twelve months

Operating cash flow$11.3M
Capital spending−$93K
Free cash flow+$11.2M
Cash conversion cycle153 days

Analysis

In Q3 2026, SkinHealth Systems generated $11.3M of operating cash flow and spent $93K on capital projects, leaving free cash flow of $11.2M. That is $1.6M more than in Q3 2025 ($9.6M).

Over the twelve months to Sep 30, 2026, operating cash flow was $23.6M; the largest uses were net borrowing (+) / repaid (−) ($122M), other investing ($4.4M), other financing ($1.8M); the cash balance fell by $107M.

Operating cash flow was $11.3M against net income of −$888K. The largest differences: payables +$5.4M, depreciation & amortization +$4.0M, other operating capital −$2.3M.

Its cash conversion cycle was 153 days (receivables 24 + inventory 194 − payables 65).

Free cash flow

SkinHealth Systems: free cash flow by quarterSkinHealth Systems: free cash flow by quarter$16.4MQ4 2024$3.0MQ1 2025$9.6MQ2 2025$9.6MQ3 2025$15.1MQ4 2025−$5.8MQ1 2026$2.2MQ2 2026$11.2MQ3 2026
Operating cash flow less capital spending.
SkinHealth Systems: operating cash flow against capital spendingSkinHealth Systems: operating cash flow against capital spendingOperating cash flowCapital spending$16.5M$74KQ4 2024$3.0M$45KQ1 2025$9.6M$92KQ2 2025$9.6M$27KQ3 2025$15.2M$139KQ4 2025−$5.6M$224KQ1 2026$2.7M$427KQ2 2026$11.3M$93KQ3 2026
Latest (Q3 2026): Operating cash flow $11.3M, Capital spending $93K.

Capital allocation, year by year

SkinHealth Systems: where the cash came from (up) and went (down), by fiscal yearSkinHealth Systems: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingCapital spendingAcquisitionsBuybacksFY2021: Operating cash flow −$28.4MFY2021: Net borrowing −$225MFY2021: Capital spending −$11.2MFY2021: Acquisitions −$22.9MFY2021FY2022: Operating cash flow −$107MFY2022: Capital spending −$10.8MFY2022: Buybacks −$160MFY2022FY2023: Operating cash flow $21.8MFY2023: Capital spending −$3.8MFY2023: Buybacks −$30.2M$21.8MFY2023FY2024: Operating cash flow $16.1MFY2024: Net borrowing −$156MFY2024: Capital spending −$756K$16.1MFY2024FY2025: Operating cash flow $37.5MFY2025: Net borrowing $219MFY2025: Capital spending −$303K$257MFY2025
Over these 5 years operating cash flow totalled −$59.6M; the largest uses were net borrowing ($382M) and buybacks ($190M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$112M
Debt$363M
Net debt$251M

SkinHealth Systems funds itself: free cash flow was $22.7M over the last twelve months, and $112M of cash and investments stands against $363M of debt.

Where the cash came from and went

SkinHealth Systems: sources (+) and uses (−) of cash, Q3 2026SkinHealth Systems: sources (+) and uses (−) of cash, Q3 2026Cash drawn (+) / kept (−)$93.7MNet borrowing (+) / repaid (−)−$83.1MOther financing−$20.2MOperating cash flow$11.3MOther investing−$970KExchange rates−$381KTaxes on employees’ shares−$272KCapital spending−$93K
SkinHealth Systems: sources (+) and uses (−) of cash, TTM to Q3 2026SkinHealth Systems: sources (+) and uses (−) of cash, TTM to Q3 2026Net borrowing (+) / repaid (−)−$122MCash drawn (+) / kept (−)$107MOperating cash flow$23.6MOther investing−$4.4MOther financing−$1.8MTaxes on employees’ shares−$1.7MCapital spending−$883KExchange rates−$139K

From profit to cash

SkinHealth Systems: net income to operating cash flow, Q3 2026SkinHealth Systems: net income to operating cash flow, Q3 2026Net income−$888KDepreciation & amortization$4.0MStock-based pay$1.4MDeferred taxes$515KReceivables−$1.6MInventory−$629KPayables$5.4MPrepaid and other assets$190KOther operating capital−$2.3MOperating cash flow$11.3M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 20262419465153
Q2 20262318964148
Q1 20262821069169
Q4 20252516352136
Q3 20253121274169
Q2 20252819572151
Q1 20253328997225
Q4 20243521166179

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Cash drawn (+) / kept (−)Free cash flow
Q3 2026$11.3M−$93K−$83.1M$93.7M$11.2M
Q2 2026$2.7M−$427K—−$1.7M$2.2M
Q1 2026−$5.6M−$224K−$20.2M$28.3M−$5.8M
Q4 2025$15.2M−$139K—−$13.3M$15.1M
Q3 2025$9.6M−$27K—−$7.4M$9.6M
Q2 2025$9.6M−$92K−$18.4M$161M$9.6M
Q1 2025$3.0M−$45K—−$3.0M$3.0M
Q4 2024$16.5M−$74K—−$11.2M$16.4M

SkinHealth Systems: income statement and cash flow

SkinHealth Systems, Q3 2026: revenue $69.2M (-2% year over year), operating margin 7.2%. The chart follows the revenue to costs, profit and cash.

SkinHealth Systems: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.